Novartis wins European approval for Jakavi
This article was originally published in Scrip
Novartis has won approval from the European Commission for its JAK inhibitor Jakavi (ruxolitinib) to treat myelofibrosis. The news follows a positive opinion from the CHMP in April this year (scripintelligence.com, 20 April 2012).
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.